NewsBenzingaLa FDA approuve le durvalumab avec l’enfortumab vedotin-ejfv pour le cancer de la vessie infiltrant le muscle La FDA approuve le durvalumab avec l’enfortumab vedotin-ejfv pour le cancer de la vessie infiltrant le muscle Benzinga 2026.11.13 18:30 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story